Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2019
Price : $35 *
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary)
- Indications Embolism and thrombosis; Ischaemia; Muscle necrosis
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms ONSIDE TEST
- 21 Dec 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2019.
- 21 Dec 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 31 Aug 2018 Biomarkers information updated